Spyre Therapeutics, Inc.

NASDAQ:SYRE

Biotechnology

Healthcare
$101.46 +1.38%

+$1.21 today

Market cap
$9.64B
Beta
3.06
P/E (TTM)
-171.1
EPS (TTM)
-$0.52
52W Low $14.00High $91.04

Volume 1.37M

Average 1.17M

SYRE Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Spyre Therapeutics, Inc.NASDAQ: SYRE

Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026

Financing cash flow turns positive

Q3 FY2026 financing cash flow was $2.02M, compared with -$4.64M a year earlier. Trailing-twelve-month financing cash flow was $759.69M. Over 3 fiscal years it compounded at +93.5% a year.

Context

  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly financing cash flow holds near $2.02M or moves back toward the trailing-twelve-month quarterly average of $189.92M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$2.02M-99.5% QoQ
Last fiscal yearDec 2025
$309.03M-24.8% YoY
LTMSep 2026
$759.69M+242.5% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+143.5%——
1 year-24.8%——
3-year CAGR+93.5%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
309.03M USD
Year-over-year change
-24.8%
4-year CAGR
+285.9%

Financing Cash Flow vs competitors

How SYRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +242.5% is the 3rd highest of 8, against a peer median of -29.8%.
  • Financing cash flow amounts to 839.5% of revenue for SYRE, versus a peer median of 92.5%.
SYRE Competitors
Financing Cash Flow for SYRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYRESpyre Therapeutics, Inc.LTM Sep 2026$759.69M USD+242.5%+93.5%839.5%
ABVXAbivax S.A.FY2025€531.94M EUR+1785.8%+154.7%—
IMUXImmunic, Inc.LTM Mar 2026$254.22M USD+330054.5%-11.9%—
ANABAnaptysBio, Inc.LTM Mar 2026$102.81M USD-191.7%—44.2%
ARDXArdelyx, Inc.LTM Mar 2026$58.47M USD+6.1%-10.2%13.7%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$52.19M USD-29.8%—623.8%
IFRXInflaRx N.V.LTM Mar 2026€6.23M EUR-77.3%+154.7%21245.3%
UPBUpstream Bio, Inc.LTM Mar 2026$3.07M USD-99.2%-37.4%92.5%
ODTXOdyssey Therapeutics, Inc.—— ———
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding SYRE) —-29.8%-10.2%92.5%

Competitors are the stored peer set for SYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(65.8M)(83.82M)(338.79M)(208.02M)(155.2M)
Depreciation & Amortization1.58M1.96M744K010M
Deferred Income Tax0(327K)000
Stock-Based Compensation8.04M7.11M25.68M44.83M37.61M
Change in Working Capital1.83M(5.5M)(5.21M)(4.53M)(5.93M)
Accounts Receivables(815K)440K375K00
Inventory0(440K)000
Accounts Payables1.07M(2.64M)218K(230K)7.65M
Other Working Capital1.58M(2.86M)(5.8M)(4.3M)(13.58M)
Other Non-Cash Items638K426K217.67M10.31M(55.73M)
Operating Cash Flow(53.72M)(80.14M)(99.91M)(157.41M)(169.25M)
Capital Expenditures(573K)(38K)000
Acquisitions (Net)003.04M00
Purchases of Investments(133.08M)(39.5M)(166.8M)(599.25M)(522.21M)
Sales of Investments111.03M96.55M39.9M245.97M371.74M
Other Investing Activities0015.48M07M
Investing Cash Flow(22.62M)57.01M(108.39M)(353.29M)(143.48M)
Debt Repayment(510K)(418K)(16K)00
Common Stock Issued042.87M169.11M236.38M314.44M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.9M222K(5.38M)5.67M(5.41M)
Financing Cash Flow1.39M42.68M361.08M410.91M309.03M
Effect of Forex Changes(15K)(106K)25K(3K)0
Net Change in Cash(74.96M)19.44M152.8M(99.79M)(3.7M)
Free Cash Flow(54.29M)(80.18M)(99.91M)(157.41M)(169.25M)

Spyre Therapeutics, Inc.

NASDAQ:SYRE

Intrinsic Alpha fair value

Locked

Current Price

$101.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.